Q32 Bio (QTTB) Q2 Loss Drops 45%
Q32 Bio (NASDAQ:QTTB), a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases, released its second quarter results on August 6, 2025. The main news was a notably reduced GAAP net loss of $0.78 per share. The company reported no revenue, consistent with expectations for a pre-commercial biotech. Operating expenses (GAAP) declined sharply following a restructuring announced in February 2025, with research and development expenses (GAAP) cut by more than half compared to Q2 2024. Overall, the quarter reflected continued focus on Q32 Bio’s lead drug candidate, bempikibart, progress in its clinical trial program, and continued financial discipline that extended its cash runway into 2027.
Source: Analyst estimates for the quarter provided by FactSet.
Q32 Bio is a biotechnology company developing new therapies for autoimmune and inflammatory diseases. Its business centers around bempikibart, an experimental therapy aimed at patients with serious immune disorders. The company recently prioritized this drug above all others, halting further internal development on its ADX-097 project.
Source Fool.com
